Iterum Therapeutics PLC（ITRM）股票分析ITRMIterum Therapeutics PLC

Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives. It offers ORLYNVAH (sulopenem in an oral tablet formulation) medicine, which is an oral penem antibiotic for the treatment of uncomplicated urinary tract infections caused by the designated microorganisms Escherichia coli, Klebsiella pneumoniae, or Proteus mirabilis in adult women. Sulopenem is a potent, thiopenem antibiotic delivered intravenously which is active against bacteria that belong to the group of organisms known as gram-negatives and cause urinary tract and intra-abdominal infections. The Company operates as a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Iterum Therapeutics PLC (ITRM) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock faces significant challenges, including a potential delisting from Nasdaq, financial instability, and lack of positive trading signals. Additionally, there are no recent positive news or catalysts to support a bullish outlook.

4 analysts cover ITRM: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 5.50.